Clinical Trial Update: Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial comparing Iberdomide with Daratumumab and Dexamethasone (IberDd) versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in relapsed or…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (daratumumab)
• iberdomide (iberdomide)

Snippet

Sponsor: Celgene | Conditions: Multiple Myeloma | Phase 3 | Status: ACTIVE_NOT_RECRUITING